{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:15:03Z","timestamp":1772226903598,"version":"3.50.1"},"reference-count":16,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: The purpose of this study is to evaluate the combined diagnostic performance of Cyclin D1 and magnetic resonance imaging (MRI) parameters in breast cancer (BC), while also assessing their ability to forecast treatment response to neoadjuvant chemotherapy (NACT), so as to provide evidence for individualized treatment strategies. Methods: A total of 154 BC patients and 148 healthy women matched with BC patients in age and BMI were enrolled in this study. Peripheral blood Cyclin D1 quantification utilized enzyme-linked immunosorbent assay (ELISA), and CA15-3 and CA27.29 (both tumor markers) measurements were made using automated electrochemiluminescence immunoassay. Magnetic resonance imaging (MRI) was conducted to obtain dynamic contrast-enhanced scans, from which radiomics parameters (PSIER, TSICS, ADC) were derived. Diagnostic accuracy for BC and predictive value for chemotherapy response were evaluated through correlation analysis (Pearson), receiver operating characteristic (ROC) curves, and multivariate regression modeling. Results: Cyclin D1 levels were elevated in BC patients compared to healthy controls and showed a positive connection with CA15-3 and CA27.29 (P&amp;lt; 0.05). The diagnostic performance of Cyclin D1 alone yielded an AUC of 0.830, whereas a combined model incorporating MRI parameters (PSIER, TSICS, and ADC) significantly improved discrimination (AUC = 0.935, sensitivity 86.36%, specificity 87.84%). During NACT, Cyclin D1 levels declined dynamically. A predictive model integrating Cyclin D1 and imaging biomarkers achieved an AUC of 0.775 for identifying poor NACT responders (sensitivity 88.37%, specificity 56.76%). Conclusions: The combination of Cyclin D1 and MRI parameters enhances both BC diagnostic accuracy and NACT efficacy prediction.<\/jats:p>","DOI":"10.5937\/jomb0-60127","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T07:34:49Z","timestamp":1755761689000},"page":"283-290","source":"Crossref","is-referenced-by-count":0,"title":["The combination of cyclin D1 and MRI radiomics parameters improves breast cancer diagnosis and NACT efficacy assessment"],"prefix":"10.5937","volume":"45","author":[{"given":"Yufei","family":"Fu","sequence":"first","affiliation":[{"name":"Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Department of Radiology, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhi","family":"Shi","sequence":"additional","affiliation":[{"name":"Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Department of Radiology, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Department of Radiology, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Department of Radiology, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Katsura C, Ogunmwonyi I, Kankam HK, Saha S. Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond) 2022; 83(2): 1-7;","DOI":"10.12968\/hmed.2021.0459"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Geng J, Jinli S, Guo W, Li H, Dan Y Gao Y Expression and clinical significance of CA125, CA153 and CEA in nipple discharge of breast cancer patients. J Med Biochem 2024; 43(2): 234-42;","DOI":"10.5937\/jomb0-45192"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Wekking D, Porcu M, De Silva P Saba L, Scartozzi M, Solinas C. Breast MRI: Clinical Indications, Recommendations, and Future Applications in Breast Cancer Diagnosis. Current Oncology Reports 2023; 25(4): 257-67;","DOI":"10.1007\/s11912-023-01372-x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Loibl S, Poortmans P Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet (London, England) 2021; 397(10286): 1750-69;","DOI":"10.1016\/S0140-6736(20)32381-3"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Qi YJ, Su GH, You C, Zhang X , Xiao Y, Jiang YZ , et al. Radiomics in breast cancer: Current advances and future directions. Cell reports Medicine 2024; 5(9): 101719;","DOI":"10.1016\/j.xcrm.2024.101719"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Montalto FI, De Amicis F Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. Cells 2020; 9(12);","DOI":"10.3390\/cells9122648"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cheng X , Sun Y, Highkin M, Vemalapally N, Jin X , Zhou B, et al. Breast Cancer Mutations HEr 2v 777L and PIK3CAH1047R Activate the p21-CDK4\/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance. Cancer Res 2023; 83(17): 2839-57;","DOI":"10.1158\/0008-5472.CAN-22-3558"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Cai Z, Wang J, Li Y, Shi Q, Jin L, Li S, et al. Over-expressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4\/6 inhibitor in breast cancer that can be reversed by PI3K\/mTOR inhibitors. Science China Life Sciences 2023; 66(1): 94-109;","DOI":"10.1007\/s11427-021-2140-8"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Yuan Z, Chen T Zhang H, Li J, Li J, Shang G. Research advances in evaluation methods for neoadjuvant therapy of tumors. Front Oncol 2025; 15: 1580360;","DOI":"10.3389\/fonc.2025.1580360"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Nardone V, Barbarino M, Angrisani A, Correale P Pastina P Cappabianca S, et al. CDK4, CDK6\/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy. Int J Mol Sci 2021; 22(16);","DOI":"10.3390\/ijms22168391"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Fang M, Wu HK, Pei Y, Zhang Y, Gao X , He Y, et al. E3 ligase MG53 suppresses tumor growth by degrading cyclin D1. Signal Transduct Target Ther 2023; 8(1): 263;","DOI":"10.1038\/s41392-023-01458-9"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Kwon HY, Park SB, Han M, Park JW, Lee Y, Han SJ, et al. Triphenyl phosphate activates estrogen receptor a\/NF-B\/ cyclin D1 signaling to stimulate cell cycle progression in human Ishikawa endometrial cancer cells. Obstetrics & Gynecology Science 2022; 65(6): 531-41;","DOI":"10.5468\/ogs.22108"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y, et al. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat Commun 2020; 11(1): 5513;","DOI":"10.1038\/s41467-020-19349-w"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Alvarez-Palomino AB, Requena-Osete J, Delgado-Morales R, Moreno-Manzano V, Grau-Bove C, Tejera AM, et al. A synthetic mRNA cell reprogramming method using CYCLIN D1 promotes DNA repair, generating improved genetically stable human induced pluripotent stem cells. Stem cells (Dayton, Ohio) 2021; 39(7): 866-81;","DOI":"10.1002\/stem.3358"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Knuth F Tohidinezhad F Winter RM, Bakke KM, Neg\u00e2rd A, Holmedal SH, et al. Quantitative MRI-based radiomics analysis identifies blood flow feature associated to overall survival for rectal cancer patients. Scientific Reports 2024; 14(1): 258;","DOI":"10.1038\/s41598-023-50966-9"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Ma C, Wang D, Tian Z, Gao W, Zang Y, Qian L, et al. USP13 deubiquitinates and stabilizes cyclin D1 to promote gastric cancer cell cycle progression and cell proliferation. Oncogene 2023; 42(29): 2249-62;","DOI":"10.1038\/s41388-023-02739-x"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Kombinacija parametara ciklina D1 i MRI radiomike pobolj\u0161ava dijagnozu raka dojke i procenu efikasnosti NACT-a"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/60127\/28524","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582602283F.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:44:02Z","timestamp":1772225042000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582602283F"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-60127","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}